NCT07207278 Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma
| NCT ID | NCT07207278 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First People's Hospital of Hangzhou |
| Condition | Signet Ring Cell Carcinoma of the Lung |
| Study Type | OBSERVATIONAL |
| Enrollment | 39 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 39 participants in total. It began in 2025-09-01 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to reveal the molecular characteristics and immune microenvironmental profile of signet ring cell carcinoma of the lung (LSRCC) in the Chinese population through integrated multi-omics analyses. The project plans to enroll formalin-fixed paraffin-embedded (FFPE) tissue samples and paired adjacent tissues from 39 patients with previously untreated LSRCC to establish a Chinese LSRCC molecular database. Whole-exome sequencing (WES) will be used to analyze gene mutations, such as single nucleotide variants (SNVs), copy number variants (CNVs), and fusion events. RNA-seq will be used to screen for differentially expressed genes (DEGs) and perform immunophenotyping, while multiplex immunohistochemistry will be employed to quantify the tumor immune microenvironment (TIME). The successful implementation of this project is expected to identify novel molecular biomarkers specific to the Chinese LSRCC population, enhance understanding of the unique immune phenotypes within this group, and-combined with clinical follow-up-establish correlations between molecular/immune signatures and therapeutic efficacy assessments, thereby providing evidence-based medical support for subsequent personalized precision diagnosis and treatment of LSRCC in this population.
Eligibility Criteria
Inclusion Criteria: 1.Histologically confirmed, previously untreated LSRCC; 2. Adequate FFPE tumor tissue and paired adjacent non-tumor tissue available; 3. Expected survival ≥ 12 weeks; 4. Patients (or their legal guardians) willing and able to provide written informed consent; 5.Availability of complete pathology and imaging data. Exclusion Criteria: 1\. Prior systemic anticancer therapy; 2. Secondary LSRCC (i.e., metastatic signet ring cell carcinoma originating from a non-lung primary site); 3. Concurrent other malignancies; 4. Incomplete pathology results, missing imaging data, or unreliable follow-up information; 5. Pregnancy or lactation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07207278 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Signet Ring Cell Carcinoma of the Lung. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07207278 currently recruiting?
Yes, NCT07207278 is actively recruiting participants. Contact the research team at shirleyz4444@zju.edu.cn for enrollment information.
Where is the NCT07207278 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT07207278 clinical trial?
NCT07207278 is sponsored by First People's Hospital of Hangzhou. The trial plans to enroll 39 participants.